5-{4-[(2,6-dichlorophenoxy)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole | 1093304-12-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 5-{4-[(2,6-dichlorophenoxy)methyl]-1H-1,2,3-triazol-1-yl}-1H-indazole
• 英文别名: 5-[4-[(2,6-dichlorophenoxy)methyl]triazol-1-yl]-1H-indazole
• CAS: 1093304-12-1
• 化学式: C₁₆H₁₁Cl₂N₅O
• 分子量: 360.202
• InChiKey: UULGXECOKAGAPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Preparation of O-desmethylvenlafaxine salts
  申请人：KRKA

  公开号：EP2119695A1

  公开（公告）日：2009-11-18

  The present invention relates to a process for the preparation of a salt of O-desmethylvenlafaxine comprising a) dissolving or suspending O-desmethylvenlafaxine in the form of its base in a liquid medium selected from the group of solvents and suspending agents; b) contacting O-desmethylvenlafaxine with a pharmaceutically acceptable acid to form a pharmaceutically acceptable salt of O-desmethylvenlafaxine wherein the pharmaceutically acceptable acid is selected from the group consisting of HCl, HBr, H2SO4, H3PO4 acetic acid, adipic acid, galactaric acid, D-gluconic acid, glutamic acid, glutaric acid, glycolic acid, hippuric acid, lactic acid, oxalic acid, methanesulphonic acid, ethanesulphonic acid, p-toluenesulphonic acid, camphorsulphonic acid, benzenesulphonic acid, malonic acid, L-ascorbic acid, naphtalene-2-sulfonic acid and benzoic acid; and c) separating the pharmaceutically acceptable salt of O-desmethylvenlafaxine from the liquid medium to recover the salt, and to pharmaceutical formulations containing these salts.

  本发明涉及一种制备奥地西米克朋盐的过程，包括a) 在从溶剂和悬浮剂组中选择的液体介质中溶解或悬浮奥地西米克朋的碱形式；b) 将奥地西米克朋与药用可接受的酸接触，形成奥地西米克朋的药用可接受盐，其中药用可接受的酸选自HCl、HBr、H2SO4、H3PO4、乙酸、己二酸、半乳糖酸、D-葡萄糖酸、谷氨酸、戊二酸、乙醇酸、马尿酸、乳酸、草酸、甲磺酸、乙磺酸、对甲苯磺酸、樟脑磺酸、苯磺酸、丙二酸、L-抗坏血酸、萘二磺酸和苯甲酸；c) 从液体介质中分离出奥地西米克朋的药用可接受盐以回收盐，并且涉及含有这些盐的制药配方。
• 5-SUBSTITUTED INDAZOLES AS KINASE INHIBITORS
  申请人：Akritopoulou-Zanze Irini

  公开号：US20090203690A1

  公开（公告）日：2009-08-13

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R 1 , R 2 , R 3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

  本发明涉及式（I）的化合物或药物可接受的盐，其中A，R1，R2，R3和m在说明书中定义。本发明还涉及制备所述化合物的方法，以及含有所述化合物的组合物，该组合物对抑制激酶如糖原合成酶激酶3（GSK-3），Rho激酶（ROCK），Janus激酶（JAK），Cdc7，AKT，PAK4，PLK，CK2，KDR，MK2，JNK1，极光激酶，pim 1和nek 2有用。
• 5-HETEROARYL SUBSTITUTED INDAZOLES AS KINASE INHIBITORS
  申请人：Abbott Laboratories

  公开号：EP2167491A1

  公开（公告）日：2010-03-31
• US20140343066A1
  申请人：——

  公开号：US20140343066A1

  公开（公告）日：2014-11-20
• US8648069B2
  申请人：——

  公开号：US8648069B2

  公开（公告）日：2014-02-11